Pembrolizumab shows promise in metastatic breast cancer with high tumor mutational burden
Disclosures:
A research grant from the Investigator-Initiated Studies Program of Merck Sharp & Dohme Corp. supported the study. Merck Sharp & Dohme provided pembrolizumab, with additional funding provided by AstraZeneca, Bayer, Boehringer-Ingelheim, Bristol Myers Squibb, Eli Lilly, Genentech and Pfizer. Alva reports a consultant/advisory role with AstraZeneca, Bristol Myers Squibb, Merck and Pfizer; research funding from Arcus Biosciences, Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Celgene, Genentech, Harpoon Therapeutics, Janssen, Merck Sharp & Dohme, Mirati Therapeutics, Progenics, Prometheus and Roche; and travel, accommodations and expenses from Bristol Myers Squibb and Merck. Please see the study for all authors’ relevant financial disclosures.